YOU ARE NOW CONNECTED TO THE TOXLINE (1981 FORWARD, NON-ROYALTY) FILE. ==EBOLA VIRUS== 6 AUTHOR Sodhi A TITLE Ebola virus disease. Recognizing the face of a rare killer. SOURCE Postgrad Med; VOL 99, ISS 5, 1996, P75-6, 78 (REF: 6) ABSTRACT Because of international travel and immigration, US physicians should be aware of the signs and symptoms of Ebola virus disease. It should be suspected in any recent traveler who presents with manifestations of viral hemorrhagic fever and in laboratory workers exposed to animals from endemic areas who show symptoms. Infected persons should be given supportive care to help them survive the acute phase of infection. Fortunately, adequate preventive measures are already in place in US hospitals and laboratories because of the prevalence of AIDS and hepatitis. However, aid should be provided to the World Health Organization and developing countries such as Zaire to support further research into the epidemiology and natural history of the virus, which may help prevent future deadly epidemics. 4 AUTHOR Borisevich IV AUTHOR Mikhailov VV AUTHOR Krasnianskii VP AUTHOR Gradoboev VN AUTHOR Lebedinskaia EV AUTHOR Potryvaeva NV AUTHOR Timan'kova GD TITLE [Development and study of the properties of immunoglobulin against Ebola fever] SOURCE Vopr Virusol; VOL 40, ISS 6, 1995, P270-3 ABSTRACT Immunoglobulin to Ebola fever has been for the first time prepared from hyperimmune equine blood sera by alcohol fractionation after Cohn. Preclinical study of the physicochemical and immunobiological properties of immunoglobulin showed that it protects up to 100% Papio hamadryas infected intramuscularly at doses of 110 to 29 LD50 Ebola virus. Scheme for the use of Ebola immunoglobulin has been experimentally validated. 5 AUTHOR Chupurnov AA AUTHOR Chernukhin IV AUTHOR Ternovoi VA AUTHOR Kudoiarova NM AUTHOR Makhova NM AUTHOR Azaev MSh AUTHOR Smolina MP TITLE [Attempts to develop a vaccine against Ebola fever] SOURCE Vopr Virusol; VOL 40, ISS 6, 1995, P257-60 ABSTRACT Data on the immunopathogenesis of Ebola fever in laboratory animals are presented and the efficacy of some methods of vaccine prophylaxis discussed. Antiviral immunity induced in guinea pigs by injection of inactivated viral agents did not protect them from infection, whereas injections of a nonlethal strain of the virus in ascending doses led to the formation of immunity preventing the development of disease upon inoculation with a lethal strain in high doses. The role of some viral peptides in the development of immune response is shown and variants of recombinant constructions for the prevention of Ebola fever are offered. 1 AUTHOR Chepurnov AA AUTHOR Dadaeva AA AUTHOR Zhukov VA AUTHOR Sizikov LP AUTHOR Merzlikin NV TITLE [Change in biochemical and hemostatic indicators in guinea pigs upon administering Ebola virus preparations] SOURCE Vopr Virusol; VOL 42, ISS 4, 1997, P171-5 ABSTRACT The biochemical and hemostatic parameters were compared in guinea pigs after inoculation of Ebola virus strains lethal and nonlethal for them and of inactivated antigen of this virus. The time course of the main hemostatic and biochemical parameters in animals challenged with the lethal strain of Ebola virus differed much from that in other groups. This permits us to hypothesize that modification of the virus in the course of adaptation to the host results in the appearance of properties boosting the enzymatic processes and, hence, in depletion and failure of antioxidant and hemostatic defence, which aggravates the pathological process.